Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic hepatitis: pathogenesis and treatment.

J A Payne1

  • 1Department of Internal Medicine Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois.

Disease-A-Month : DM
|March 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thermal damage to the skin from 8.2 and 95 GHz microwave exposures in swine.

Biomedical physics & engineering express·2024
Same author

Sex pheromone of hickory shuckwormCydia caryana Development of an effective field Lure.

Journal of chemical ecology·2013
Same author

Male-specific volatiles from nearctic and Australasian true bugs (Heteroptera: Coreidae and Alydidae).

Journal of chemical ecology·2013
Same author

Tobacco-mosaic-virus-induced increase in abscisic-acid concentration in tobacco leaves: : Intracellular location in light and dark-green areas, and relationship to symptom development.

Planta·2013
Same author

Differential distribution of the KCl cotransporter KCC2 in thalamic relay and reticular nuclei.

The European journal of neuroscience·2004
Same author

Seasonal variation in copper-mediated low-density lipoprotein oxidation in vitro is related to varying plasma concentration of oxidised lipids in summer and winter.

Free radical research·2003
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

This review discusses current treatments for chronic viral, autoimmune, and drug-induced hepatitis. It highlights accurate diagnosis, antiviral therapies for hepatitis B, and immunosuppression for autoimmune hepatitis.

Area of Science:

  • Hepatology
  • Immunology
  • Pharmacology

Background:

  • Chronic active liver disease encompasses viral hepatitis (B, delta, non-A, non-B), autoimmune hepatitis, and drug-induced liver injury.
  • Understanding the pathophysiology of these conditions is crucial for effective treatment strategies.
  • Accurate diagnosis is paramount, with limitations of conventional techniques discussed.

Purpose of the Study:

  • To review current therapeutic approaches for various forms of chronic active hepatitis.
  • To integrate recent advances in understanding disease pathogenesis with treatment modalities.
  • To provide a framework for the use of antiviral and immunomodulatory agents.

Main Methods:

  • Literature review of current therapies and recent advances in chronic liver disease.

Related Experiment Videos

  • Discussion of diagnostic challenges and limitations.
  • Analysis of data from antiviral therapies (adenosine arabinoside, acyclovir) and alpha-interferon.
  • Review of immunomodulatory agents and immunosuppressive therapy for autoimmune hepatitis.
  • Consideration of drug cessation for drug-induced liver disease and liver transplantation for end-stage disease.

    • Main Results:

    • Antiviral therapies show promise for chronic hepatitis B, with early data on adenosine arabinoside, acyclovir, and alpha-interferon presented.
    • Immunosuppressive therapy can be effective for autoimmune hepatitis, with guidelines for corticosteroid use and management of hazards provided.
    • Cessation of the offending agent is typically curative for drug-induced chronic hepatitis.
    • Liver transplantation remains an option for end-stage liver disease.

    Conclusions:

    • Treatment of chronic active hepatitis requires accurate diagnosis and tailored therapeutic strategies.
    • Advances in understanding pathogenesis inform the use of antiviral and immunomodulatory drugs.
    • Management involves a spectrum of interventions from drug cessation to transplantation.